Two Secondary Primary Malignancies after Bortezomib Therapy for Multiple Myeloma: A Single-center Experience.

Author: Tian-Jiao GUO ^{1
,

2} ; Xiao-Jun HUANG ³ ; Lei WEN ³ ; Jin LU ³
Author Information

1. Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044
2. Department of Hematology, Fu Xing Hospital, Capital Medical University, Beijing 100038, China.
3. Department of Hematology, Peking University People's Hospital and Peking University Institute of Hematology, Beijing 100044, China.
Publication Type:Journal Article
MeSH: Aged; Antineoplastic Agents; therapeutic use; Bortezomib; therapeutic use; Female; Humans; Male; Middle Aged; Multiple Myeloma; drug therapy
From: Chinese Medical Journal 2017;130(2):239-241
CountryChina
Language:English